These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11365806)

  • 1. Another expensive drug for your cocktail.
    Gilden D
    GMHC Treat Issues; 1998 Sep; 12(9):3-6. PubMed ID: 11365806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA approves efavirenz. Food and Drug Administration.
    Highleyman L
    BETA; 1998 Oct; ():3. PubMed ID: 11365987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA approves Sustiva (efavirenz) capsules, first once-daily anti-HIV drug. Food and Drug Administration.
    Res Initiat Treat Action; 1998 Oct; 4(6):13-4. PubMed ID: 11365915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration.
    Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz (SUSTIVA) approved.
    James JS
    AIDS Treat News; 1998 Oct; (No 304):1-4. PubMed ID: 11365862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drug approved.
    AIDS Policy Law; 1998 Oct; 13(18):12. PubMed ID: 11365934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustiva (efavirenz) is approved.
    Vazquez E
    Posit Aware; 1998; 9(6):17. PubMed ID: 11366471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment].
    Allerg Immunol (Paris); 1998 Oct; 30(8):268-70. PubMed ID: 9846197
    [No Abstract]   [Full Text] [Related]  

  • 9. Efavirenz (Sustiva) on fast-track for FDA accelerated approval. Food and Drug Administration.
    Baker R
    BETA; 1998 Jul; ():9. PubMed ID: 11365571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination.
    James JS
    AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Now approved: Sustiva in combination offers patients a new first-line therapy.
    Fac Notes (New Orleans La); 1998; 10(6):10. PubMed ID: 11366140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NNRTIs: a neglected class.
    Cadman J
    GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz approved in the U.S.
    TreatmentUpdate; 1998 Oct; 10(8):3-4. PubMed ID: 11365876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadened access to Sustiva.
    Bornhoeft MA
    Body Posit; 1998 Jan; 11(1):13. PubMed ID: 11365007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efavirenz newly approved.
    Newsline People AIDS Coalit N Y; 1998; ():31. PubMed ID: 11367501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMP 266 (Sustiva) expanded access.
    Vazquez E; Whitfield L
    Posit Aware; 1997; 8(6):12. PubMed ID: 11364850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New study shows efavirenz effective with d4T and 3TC.
    AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz expanded access.
    Highleyman L
    BETA; 1998 Jan; ():4. PubMed ID: 11364975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.